Effects of a new 75 g glucose- and high fat-containing cookie meal test on postprandial glucose and triglyceride excursions in morbidly obese patients.


Journal

Endocrine journal
ISSN: 1348-4540
Titre abrégé: Endocr J
Pays: Japan
ID NLM: 9313485

Informations de publication

Date de publication:
28 Jun 2022
Historique:
pubmed: 28 1 2022
medline: 2 7 2022
entrez: 27 1 2022
Statut: ppublish

Résumé

A new meal tolerance test (MTT) using a 75 g glucose- and high fat-containing meal was applied to classify glucose intolerance in morbidly obese patients. According to the MTT data, the concordance rate of diagnosis was 82.5% compared to the 75 g oral glucose tolerance test (OGTT) in patients with normal glucose tolerance (NGT, n = 40). In the NGT patients, the insulinogenic index (r = 0.833), Matsuda index (r = 0.752), and disposition index (r = 0.845) calculated from the MTT data were each significantly (p < 0.001) correlated with those derived from the OGTT data. However, in patients with impaired glucose tolerance (IGT, n = 23) or diabetes mellitus (DM, n = 17), the postprandial glucose levels post-MTT were significantly lower than those post-OGTT, without increases in the postprandial insulin levels post-MTT. Thus, the severity of glucose intolerance measured by the MTT was milder than that indicated by the OGTT. Plasma levels of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) were increased at the postprandial state, but only the GIP levels post-MTT were significantly higher than those post-OGTT. The enhancement of glucose disposal rates in patients with NGT or IGT after the MTT was associated with increased GIP levels. The postprandial hypertriglyceridemia induced by the MTT was associated with insulin resistance, but it was not associated with the impaired insulinogenic index or the disposition index. These results indicate that the new MTT is clinically useful to evaluate both abnormal glucose and triglyceride excursions caused by abnormal insulin sensitivity and secretions of insulin and gut hormones in morbidly obese patients.

Identifiants

pubmed: 35082201
doi: 10.1507/endocrj.EJ21-0615
doi:

Substances chimiques

Blood Glucose 0
Insulin 0
Triglycerides 0
Gastric Inhibitory Polypeptide 59392-49-3
Glucose IY9XDZ35W2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

689-703

Auteurs

Yukako Yamamoto (Y)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Yuki Ozamoto (Y)

Department of Bariatric and Metabolic Surgery, Omi Medical Center, Shiga 525-8585, Japan.

Masaki Kobayashi (M)

Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation, Gunma University, Gunma 371-8512, Japan.

Yuji Tezuka (Y)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Choka Azuma (C)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Osamu Sekine (O)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Jun Ito-Kobayashi (J)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Miki Washiyama (M)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Yasumitsu Oe (Y)

Department of Bariatric and Metabolic Surgery, Omi Medical Center, Shiga 525-8585, Japan.

Masanori Iwanishi (M)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Takeshi Togawa (T)

Department of Bariatric and Metabolic Surgery, Omi Medical Center, Shiga 525-8585, Japan.

Akeo Hagiwara (A)

Department of Bariatric and Metabolic Surgery, Omi Medical Center, Shiga 525-8585, Japan.

Tadahiro Kitamura (T)

Metabolic Signal Research Center, Institute for Molecular and Cellular Regulation, Gunma University, Gunma 371-8512, Japan.

Akira Shimatsu (A)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Atsunori Kashiwagi (A)

Department of Diabetes and Endocrinology, Omi Medical Center, Shiga 525-8585, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH